Serious adverse events and compensation in registration trials: a review of data from a Japanese university hospital

Miho Watanabe, Soichiro Tajima, Rumi Katashima, Toshiko Miyamoto, Makiko Yamagami, Kazuo Minakuchi and Hiroaki Yanagawa*

Abstract

Background: Clinical trials leading to regulatory approval, or registration trials, play a central role in the development of drugs and medical devices. The contribution of support staff, such as the clinical research coordinator (CRC) and administrative officers, in registration trials is now widely recognized. Attending to serious adverse events is an important duty of the CRC and investigators alike, and managing these complications and compensation constitutes a key responsibility. We retrospectively examined the frequency of serious adverse events and compensation events reported from 2007 through 2011 at Tokushima University Hospital, an academic hospital in rural Japan. We present herein the results of our analysis.

Results: Over the five-year period, 284 subjects participating in 106 registration trials experienced a total of 43 serious adverse events, and eight compensation events were documented. Among the serious adverse events, 35 (81.4%) were considered not related to the investigational drug, and 17 (39.5%) resulted in withdrawal of the study drug. Patients with malignant diseases experienced serious adverse events significantly more frequently compared to those with non-malignant diseases (28.3% versus 8.2%, respectively; \( P < 0.01 \)).

Conclusions: The CRC should be vigilant for serious adverse events in oncology clinical trials due to the generally higher frequency of these complications in subjects with malignancy. However, on an individual basis, the CRC may be seldom involved in the process for compensating serious adverse events. Therefore, the CRC’s ability to share such experiences may serve as an opportunity for educating clinical trial support staff at the study site as well as those at other sites. However, further study is warranted to determine the role of the clinical trial support staff in optimizing methods for managing adverse events requiring compensation in registration trials.

Keywords: Registration trial, Serious adverse events, Compensation, Clinical research coordinator, Oncology

Background

Clinical research plays an important role in improving the quality of medical practice. In particular, registration trials leading to the approval of drugs and medical devices are paramount in the development of drugs and medical devices. In 1996, the Good Clinical Practice (GCP) was introduced as a global standard, and since the Japanese introduction of it in 1997, the infrastructure for registration trials in Japan has improved. The contribution of clinical trial support staff, such as clinical research coordinators (CRC) and administrative officers, is now widely recognized.

CRC must engage not only in the scientific and ethical pursuit of registration trials, but also in assuring standards of quality by coordinating the activities and conduct of participants, investigators, sponsors, and various hospital staff. Among these duties, adverse event management, including proper and timely reporting to sponsors, is a key responsibility. CRC, as well as investigators, should pay close attention to serious adverse events, partly because these events may lead to compensation events which require additional resources and the involvement of administrative officers.

* Correspondence: niseko@tokushima-u.ac.jp
1 Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Kuramoto-cho 2, Tokushima 770-8503, Japan
Full list of author information is available at the end of the article
However, on an individual basis, the clinical trial support staff may have limited experience dealing with serious adverse events and compensation. Therefore, reviewing the shared experience of the CRC may offer a valuable opportunity for collecting and analyzing data on the frequency of these events, and provide some insight into appropriate methods for managing them. Accordingly, we retrospectively examined the incidence of serious adverse events and related compensation at Tokushima University Hospital. We present herein the results of our analysis.

Methods
We retrospectively reviewed records from the institutional review board (IRB) of Tokushima University Hospital for the period 2007 through 2011. A serious adverse event was defined by the criteria established in the International Conference on Harmonisation (ICH) harmonised tripartite guideline E2A [1]. We classified a serious adverse event as an untoward medical occurrence which at any dose: 1) resulted in death, 2) was life-threatening, 3) required inpatient hospitalisation or prolonged an existing hospitalisation, 4) resulted in persistent or significant disability or incapacity, 5) was a congenital anomaly/birth defect, or 6) others. We compared the frequency of events and subjects stratified by malignant and non-malignant diseases and applied a chi-squared test to analyze differences. A two-sided P-value <0.05 was considered to be statistically significant. This study was approved by the Ethics Committee of Tokushima University Hospital.

Results
Number of registration trials and subjects over the five-year period
Table 1 presents the number of registration trials approved by the IRB at Tokushima University Hospital each year as well as the frequency of subjects with malignant diseases and non-malignant diseases. Data for the year 2007 pertained to trials continuing from previous years as well as those approved in the current year. For 2008–2011, clinical trials approved in each respective year were included. As shown in Table 1, clinical studies in non-malignant diseases comprised a greater proportion of registration trials conducted at Tokushima University Hospital compared to those in malignant diseases.

Frequency of serious adverse events
As indicated in Table 2, a total of 43 serious adverse events were reported during the five-year period. Among these, a relationship between the adverse event and investigational drug was ruled out in 14 (66.6%) of 21 events occurring in patients with malignant diseases and in 21 of 22 (95.5%) events in those with non-malignant diseases. Eleven of 21 (52.4%) events in patients with malignant diseases and 6 of 22 (27.3%) events in those with non-malignant diseases led to the withdrawal of the study drug. Examining the numbers of subjects with severe adverse events, a significantly greater proportion of subjects with malignant disease (28.3%; 15 of 53) experienced serious adverse events compared to those with non-malignant disease (8.2%; 19 of 231; P < 0.01).

Subjects with multiple serious adverse events
Among the 25 oncology registration trials, two subjects experienced two serious adverse events, and two subjects experienced three. None of the subjects in the oncology trials experienced more than three. Among the 81 non-oncology registration trials, one subject experienced two serious adverse events, and another had three. Similar to the oncology trials, none of the subjects in the non-oncology trials had more than three (Table 3).

Frequency of compensation events and subjects seeking compensation
Over the five-year period, eight compensation events were reported in a total of seven subjects at Tokushima University Hospital. Among these, seven compensation events occurred during the oncology registration trials, and one was associated with a non-oncology trial.

Discussion
Among the various roles assigned to the CRC, adverse event management, including proper and timely reporting

Table 1 Frequency of studies and subjects in oncology and non-oncology registration trials at Tokushima University Hospital: 2007 to 2011

| Year | Number of registration trials (%) | Number of subjects (%) |
|------|-----------------------------------|------------------------|
|      | Malignant diseases                | Non-malignant diseases | Total     |
|      | 2007 11 (23.4)                    | 36 (76.6)              | 47 (100)  |
|      | 2008 1 (6.7)                      | 14 (93.3)              | 15 (100)  |
|      | 2009 4 (28.6)                     | 10 (71.4)              | 14 (100)  |
|      | 2010 4 (28.6)                     | 10 (71.4)              | 14 (100)  |
|      | 2011 5 (31.3)                     | 11 (68.7)              | 16 (100)  |
| Total| 25 (23.6)                         | 81 (76.4)              | 106 (100) |

| Year | Malignant diseases                | Non-malignant diseases | Total     |
|------|-----------------------------------|------------------------|
|      | 2007 28 (20.7)                    | 107 (79.3)             | 135 (100) |
|      | 2008 5 (7.7)                      | 60 (92.3)              | 65 (100)  |
|      | 2009 8 (24.2)                     | 25 (75.8)              | 33 (100)  |
|      | 2010 10 (31.3)                    | 22 (68.7)              | 32 (100)  |
|      | 2011 2 (10.5)                     | 17 (89.5)              | 19 (100)  |
| Total| 53 (18.7)                         | 231 (81.3)             | 284 (100) |
Compensation for injured and deceased research subjects has been a long-standing issue [6]. In Japan, sponsors of registration trials are required to prepare for the provision of compensation. Details of compensation are not defined by regulation. Instead, the guideline by the Japan Pharmaceutical Industry Legal Affairs Association [7] is used by most of the sponsors. Japan has universal health coverage by employee-based and community-based social health insurance [8]. In the system, co-payment rate is 30% in general, and the rest is paid by public insurance. Acting of co-payment by sponsors is considered as compensation in Japan. In serious cases, such as fatal cases, monetary compensation is considered.

Because compensation is considered regardless of fault even when the relationship between the adverse event and investigational drug is indeterminate, the investigator’s decision regarding the potential association is highly important. In the present study, a relationship could not be ruled out in 8 of the 43 serious events. Participants’ consent for compensation is mandatory for registration trials. Nevertheless, in most cases, staffs of medical institution propose claims for compensation to injured participants practically. In such cases, the CRC should coordinate the efforts of sponsors, study participants, investigators, and administrative offices from all institutions with the aim of protecting the subjects’ rights, and that is the first role of CRC in compensation.

In 2005, we developed a manual to manage compensation events following discussions with the administrative office. In general, it takes time to decide relationship between the adverse event and investigational drug, and participants should pay their co-payment before the decision. As a practice in Tokushima University Hospital, patients’ payment of co-payment is postponed until the final decision of the relationship. Even if payment of co-payment by sponsors starts, it will be ceased when the condition becomes stable. Long time follow-up of participants is also important and these points are shown in our manual. Suzuki et al. [4] also compiled a checklist to manage compensation at a Japanese university hospital. Since individual CRC may seldom participate in compensation events involving their assigned subjects, it may be helpful for those who have dealt with such events to share their experiences with other CRC at the study site as well as with those from other sites.

In the present study, subjects with malignant disease experienced serious adverse events more often than those with non-malignant disease. Conversely, the relationship with the investigational drug was ruled out more frequently in cases with non-malignant diseases than in those with malignant diseases. These findings suggest that the difference was not related to the higher incidence of disease-related death among oncology trials. In a Spanish survey of CRCs attending an educational course on oncology clinical

### Table 2 Annual and total number of serious adverse events in subjects with malignant diseases and non-malignant diseases

| Year | Malignant diseases | Non- malignant diseases | Total |
|------|-------------------|------------------------|-------|
| 2007 | 5                 | 3                      | 8     |
| 2008 | 4                 | 3                      | 7     |
| 2009 | 6                 | 3                      | 9     |
| 2010 | 2                 | 9                      | 11    |
| 2011 | 4                 | 4                      | 8     |
| Total| 21                | 22                     | 43    |

### Table 3 Frequency of serious adverse events in subjects with malignant diseases and non-malignant diseases

| Frequency of SAE | Number of subjects |
|------------------|--------------------|
|                  | Malignant diseases | Non- malignant diseases | Total |
| 0                | 38                 | 212                   | 250   |
| 1                | 11                 | 17                    | 28    |
| 2                | 2                  | 1                     | 3     |
| 3                | 2                  | 1                     | 3     |
| Total            | 53                 | 231                   | 284   |
Conclusions

The present study evaluated serious adverse events and compensation in registration trials restricted to a university hospital in rural Japan. We found that subjects with malignant diseases experienced serious adverse events and required compensation more frequently than those with non-malignant diseases. From the perspective of the clinical trial support staff, it is necessary to establish more effective systems for managing serious adverse events and compensation. However, given the limitations of our retrospective study, further research is warranted to determine the role of clinical trial support staff in developing a suitable infrastructure for these systems in clinical research.

Competing interests

The authors declare that they have no competing interests in relation to this article.

Authors’ contributions

MW, ST and HY conceived the study, collected and analyzed the data, and drafted the manuscript. RK, TM, and MY participated in the study design and assisted in drafting the manuscript. KM participated in the study design and assisted in drafting the manuscript. All authors have read and approved the final manuscript.

Acknowledgements

The authors would like to thank Akiyo Akaishi, Tsugumi Amou, Michiko Yoshimaru, Natsuko Ise, Akari Futami, Chiho Sato, Noriko Urakawa, Akane Suzuki, Reiko Tomioka, the Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Kuramoto-cho 2, Tokushima 770-8503, Japan. 2Institutional Review Board, Tokushima University Hospital, Kuramoto-cho, Tokushima, Japan.

Author details

1Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Kuramoto-cho 2, Tokushima 770-8503, Japan. 2Institutional Review Board, Tokushima University Hospital, Kuramoto-cho, Tokushima, Japan.

Received: 21 November 2013 Accepted: 11 April 2014
Published: 17 April 2014

References

1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH Harmonised Tripartite Guideline. Clinical safety data management: Definitions and standards for expedited reporting E2A. [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf]
2. Fukutomi J, Terada J, Koike N, Ishii K, Kimura K, Kobayashi S. St. Marianna Hospital ni okeru yuugaijishou heno taiou to hoshou. [Management of adverse events and compensation in St. Marianna University School of Medicine Hospital]. Jpn J Clin Pharmacol Ther 2002, 33:53–59.
3. Yamada N, Hirayama R, Matsuura K, Onda A, Kawai M, Ishizaki S, Nagamatsu A, Watanabe K, Todai C, Ogura K, Arakawa Y, Omata M: A manual to facilitate clinical data collection from the doctors in other hospitals whom subjects consult for serious adverse events during clinical trials. Jpn J Clin Pharmacol Ther 2008, 39:11–115.
4. Suzuki R, Iwasaki Y, Yamamoto Y, Asano K: Hoshou taionoikeru CRC you checklist no sakusei to sono unnyou ni tuite [Development and application of CRC checklist for management of compensation]. Clin Res Professionals 2012, 28:30–33.
5. Poston RD, Buescher CR. The essential role of the clinical research nurse (CRN). Urol Nurs 2010, 30(1):55–63, 77.
6. Steinbrook R. Compensation for injured research subjects. N Engl J Med 2006, 354:1871–1873.
7. Japan Pharmaceutical Industry Legal Affairs Association: Compensation guideline for injured research subjects. [www.ihoken.or.jp/guideline/2_revisionguideline.pdf]
8. Ikegami N, Yoo BK, Hasmihoto H, Matsumoto M, Ogata H, Babazono A, Watanabe R, Shibuya K, Yang BM, Reich MP, Kobayashi Y. Japanese universal health coverage: evolution, achievements, and challenges. Lancet 2011, 378:1106–1115.
9. Rico-Villademoros F, Hernandez T, Sanz JL, Lopez-Alonso A, Salamanca Q, Camps C, Rossell R: The role of the clinical research coordinator – data manager – in oncology clinical trials. BMC Med Res Meth 2004, 4:5.

Cite this article as: Watanabe et al.: Serious adverse events and compensation in registration trials: a review of data from a Japanese university hospital. BMC Research Notes 2014 7:245.

doi:10.1186/1756-0500-7-245

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit